<DOC>
	<DOCNO>NCT01462006</DOCNO>
	<brief_summary>Idiopathic pulmonary fibrosis ( IPF ) illness characterize progressive decline lung function premature death respiratory failure . Fibrocytes novel population bone marrow-derived circulating progenitor cell show traffic lung contribute fibrosis animal model pulmonary fibrosis , whose number correlate degree fibrosis survival human pulmonary fibrosis . The investigator propose test hypothesis therapy mTOR inhibitor , sirolimus , reduce number circulate fibrocytes patient IPF . The investigator propose test hypothesis short-term pilot trial sirolimus patient IPF determine effect number phenotype circulate fibrocytes .</brief_summary>
	<brief_title>Double-blind Placebo-controlled Pilot Study Sirolimus Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Male female patient 2185 year age 2 . Individuals diagnose IPF , base : clinical symptom consistent idiopathic pulmonary fibrosis ( IPF ) &gt; 3 month duration , plus histologically diagnosed UIP diagnostic chest high resolution CT feature UIP , plus negative workup know cause UIP 3 . Ability understand write informed consent form comply requirement study . 1 . Clinical feature know diagnosis active infection , include untreated latent tuberculosis 2 . Clinical feature know diagnosis malignancy 3 . Known diagnosis interstitial lung disease IPF include limited sarcoidosis , hypersensitivity pneumonitis , nonspecific interstitial pneumonia ( NSIP ) . 4 . History clinically significant environmental exposure know cause interstitial lung disease ( include limit drug , asbestos , silica , beryllium , radiation , domestic bird , etc ) . 5 . Diagnosis connective tissue disease ( include limit scleroderma , SLE , rheumatoid arthritis ) vasculitides accord American College Rheumatology criterion . 6 . Systolic blood pressure &lt; 100 &gt; 145 mm Hg diastolic blood pressure &lt; 50 &gt; 90 mmHg 7 . Evidence active infection within 1 week prior enrollment . 8 . Recently start ( &lt; 8 week prior baseline visit ) plan cardiopulmonary rehabilitation program conclusion study 9 . History unstable deteriorate cardiac disease , include limited : myocardial infarction , coronary artery bypass surgery angioplasty within past 6 month , congestive heart failure require hospitalization within past 6 month , uncontrolled arrhythmia 10 . History unstable deteriorate neurologic disease , include limited : TIAs stroke 11 . Pregnant lactating female . Females child bear potential require negative serum urine pregnancy test prior treatment agree practice abstinence prevent pregnancy least barrier method birth control . 12 . Liver panel specific limit screen : Total bilirubin &gt; 1.5fold upper limit normal , AST , ALT alkaline phosphatase &gt; 3fold upper limit normal screening . 13 . Hematology outside specify limit , WBC &lt; 2,500/ mm3 , hematocrit &lt; 30 , platelet &lt; 100,000/mm3 screening . 14 . Investigational therapy indication within 28 day prior treatment . 15 . Current treatment drug strong inhibitor CYP3A4 Pgp , namely bromocriptine , cimetidine , cisapride , clotrimazole , danazol , diltiazem , fluconazole , HIVprotease inhibitor ( e.g. , ritonavir , indinavir ) , metoclopramide , nicardipine , troleandomycin , verapamil 16 . Inability unwillingness comply requirement trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>